CITATION — REFERENCE ENTRY
pegloticase · fitzgerald-2020-acr-gout-guideline
- Citation
- fitzgerald-2020-acr-gout-guideline
- Claim ID
- pegloticase
- Assertion
- The ACR strongly recommends switching to pegloticase when xanthine oxidase inhibitors, uricosurics and other interventions have failed to reach the urate target and the patient still has frequent flares or non-resolving tophi.
- Quote
Switching to pegloticase over continuing current ULT is strongly recommended for patients with gout for whom XOI treatment, uricosurics, and other interventions have failed to achieve the SU target, and who continue to have frequent gout flares (≥2 flares/year) OR who have nonresolving subcutaneous tophi.
- Quote language
- en
- Locator
- section: Ongoing ULT management
Available in